disulfide bond

PACMA 31 is an irreversible and covalent inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. PACMA 31 significantly suppresses ovarian tumor growth and exhibits tumor targeting ability.

Glutathione oxidized (L(-)-Glutathione) is a GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

Allyl propyl disulfide is an organic compound with a double bond and a disulfide group that is used in organic synthesis and biochemical experiments.

2-(butan-2-yldisulfanyl)butane is a compound containing a disulfide bond that is used in organic synthesis and biochemical experiments.

EcDsbB-IN-9 is a specific EcDsbB inhibitor, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria.

EcDsbB-IN-12 (4,5-dichloro-2-[(2-chlorophenyl)methyl]pyridazin-3-one) targets disulfide bond forming enzyme,and is a novel potent specific inhibitor of EcDsbB.

DM4-SMe is a cytotoxic part of antibody-drug conjugates (ADCs) and a metabolite of antibody-maytansin conjugates (AMCs) and tubulin inhibitors, which can also be stabilized by disulfide bonds or thioether The bond binds to the antibody. The IC50 of DM4-SM

DBCO-S-S-PEG3-biotin is a cleavable reagent for the introduction of a biotin moiety to azide-containing biomolecules using copper-free Click Chemistry. The disulfide bond in this linker can be cleaved with reducing agents such as DTT, BME, and TCEP to remove the biotin label. PEG linkers can also be used in the synthesis of PROTACs.

Azido-PEG3-SS-NHS is a three-unit polyethylene glycol (PEG) linker with an azide group, a cleavable disulfide bond, and an N-hydroxysuccinimide ester, primarily used in the synthesis of antibody-drug conjugates (ADCs) [1].

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .

CL2A is a pH-sensitive, cleavable PEG8- and triazole-containing PABC-peptide-mc linker, characterized by its ability to induce a bystander effect. It forms a disulfide bond with an antibody at a cysteine residue. Labetuzumab govitecan utilizes this linker for its drug conjugation[1].

2N12B is an ionizable cationic lipid containing a disulfide bond (pKa = 6.5), utilized in the creation of lipid nanoparticles (LNPs) for the delivery of siRNA both in vitro and in vivo.

TDK-HCPT is a small molecule conjugate that links glutathione-sensitive thiamine disulfide with the chemotherapeutic agent 10-hydroxycamptothecin through a thioacetal bond. It targets tumor cells and prolongs the retention of the chemotherapeutic drug within these cells. TDK-HCPT inhibits tumor growth, induces apoptosis (apoptosis) in tumor cells, and exhibits antitumor activity.

Felypressin acetate (PLV-2) is an agonist of vasopressin 1 and acts on all arginine vasopressin receptors 1AS. Felypressin acetate can be used in dental procedures.

YK-5-252 is a dual action combretastatin A-4 (CA-4) prodrug which releases CA-4 through a disulfide bond cleavage mechanism and contains a near-infrared (NIR) fluorophore.

SPDB is a degradable ADC linker that can be used to synthesize antibody-drug conjugates. SPDB is a small fragment attached to the DM4 conjugate and conjugated to the antibody using a disulfide bond.

Amylin (1-37) (human) (hIAPP (1-37)), a peptide hormone located in pancreatic beta-cell secretory granules, is characterized by an amidated C-terminus and a disulfide bond between cysteine residues 2 and 7 [1].

CHRG01, a biologically active peptide, originates from the C-terminal amino acids 54 to 67 of human β-defensin 3 (hBD-3), with a modified structure wherein all cysteine (Cys) residues are replaced by serine (Ser) to eliminate disulfide bond linkages. Like its parent compound hBD-3, CHRG01 exhibits antimicrobial properties that are dependent on electrostatic interactions.

Thrombospondin-1 (TSP-1)-derived CD36 binding motif is a bioactive peptide cyclized by a disulfide bond, critical for TSP-1-CD36 interaction. Involved in cancer metastasis, tumor adhesion, and angiogenesis, this matrix-bound glycoprotein-origin peptide competitively inhibits platelet aggregation and tumor metastasis.

113-O12B is an ionizable cationic lipidoid containing a disulfide bond, utilized in the generation of lipid nanoparticles (LNPs) for mRNA delivery [1].

113-O16B, an ionizable cationic lipidoid featuring a disulfide bond, is utilized in producing lipid nanoparticles (LNPs) for mRNA delivery [1].

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.

Thioredoxin reductase peptide, corresponding to residues 53-67 in thioredoxin reductase (TrxR), is used in thioredoxin reductase research. Mammalian thioredoxin reductase (TR) catalyzes the reduction of the redox-active disulfide bond of thioredoxin (Trx) and is structurally and mechanistically similar to glutathione reductase, except for a C-terminal 16-amino acid extension containing a rare vicinal selenylsulfide bond.

Thioredoxin reductase peptide acetate corresponds to residues 53–67 in thioredoxin reductase (TrxR), used in thioredoxin reductase research.Mammalian thioredoxin reductase (TR) catalyzes the reduction of the redox-active disulfide bond of thioredoxin (Trx